CBMS navigation bar CBMS link MITS link BSV link CRP link

Joint Vaccine Acquisition Program (JVAP)

About
The CBMS-Joint Vaccine Acquisition Program (JVAP) develops, produces, and stockpiles U.S. Food and Drug Administration (FDA)–licensed vaccine systems to protect the Warfighter against biological agents. The CBMS-JVAP consolidates the Department of Defense (DoD)'s efforts for advanced development, testing, FDA licensing, production, and storage of biological defense vaccines.
JVAP Logo

The CBMS-JVAP's impressive portfolio of fielded products to the Warfighter include the Anthrax Vaccine Adsorbed (AVA) Biothrax, the Smallpox Vaccine ACAM2000, and the Vaccinia Immune Globulin, a treatment for rare adverse reactions to the smallpox vaccine. The CBMS-JVAP's advanced development portfolio includes the plague vaccine, botulinum toxin vaccine, and filovirus vaccine.

Mission
To develop, produce, and stockpile U.S. Food and Drug Administration (FDA)–licensed vaccine systems to protect the Warfighter against biological warfare agents. JVAP consolidates the Department of Defense's efforts for the advanced development, testing, FDA licensing, production, and storage of biological defense vaccines.

Products  
Anthrax Vaccine (AVA) Recombinant Botulinum Vaccine (rBV)
Recombinant Plague Vaccine (rF1V) Smallpox Vaccine System (SMALLPOX)
Trivalent Filovirus Vaccine (Filo)  

JVAP Capabilities Image

Contact Information
Phone: 301.619.7124
E-mail: usarmy.detrick.cbms.mbx.info@mail.mil

Last updated: 8/29/2012 9:35:02 AM